ACH
Accendra Health, Inc.
NYSE · Healthcare · Medical - Distribution · US
$1.21
−0.82%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.6B | 2.8B | 10.7B | 10.3B | 10.0B |
| Cost of Revenue | 1.5B | 1.5B | 8.5B | 8.2B | 8.1B |
| Gross Profit | 1.2B | 1.3B | 2.2B | 2.1B | 1.8B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 1.0B | 1.1B | 1.9B | 1.8B | 1.6B |
| General & Admin Expense | — | — | 1.9B | — | — |
| Selling & Marketing Expense | — | — | 17.9K | — | — |
| Other Expenses | 55.0M | — | 517.1M | 207.1M | 128.6M |
| Total Operating Expenses | 1.1B | 1.1B | 2.4B | 2.0B | 1.7B |
| Cost and Expenses | 2.6B | 2.5B | 10.9B | 10.2B | 9.8B |
| Operating Income (EBIT) | 95.8M | 221.7M | (207.8M) | 104.5M | 142.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 123.8M | 107.2M | 143.8M | 157.9M | 128.9M |
| Net Interest Income | (123.8M) | (107.2M) | (143.8M) | (157.9M) | (128.9M) |
| Other Non-Op Income/Expense | (211.3M) | (323.7M) | (149.6M) | (159.2M) | (132.0M) |
| Non-Operating Income (excl Interest) | 87.4M | 216.5M | 5.8M | 1.3M | 3.1M |
| EBT (Pre-Tax Income) | (115.5M) | (102.0M) | (357.4M) | (54.7M) | 10.9M |
| Income Tax Expense | (4.9M) | 729.0K | 5.3M | (13.4M) | (11.5M) |
| Bottom Line | |||||
| Net Income | (302.1M) | (1.1B) | (362.7M) | (41.3M) | 22.4M |
| Earnings from Cont. Ops | (110.6M) | (102.7M) | (362.7M) | (41.3M) | 22.4M |
| Earnings from Discont. Ops | (191.6M) | (998.0M) | — | — | — |
| Bottom Line Net Income | (302.1M) | (1.1B) | (362.7M) | (41.3M) | 22.4M |
| Per Share | |||||
| Basic EPS | ($3.91) | ($14.31) | ($4.73) | ($0.54) | $0.30 |
| Diluted EPS | ($3.91) | ($14.31) | ($4.73) | ($0.54) | $0.29 |
| Revenue Per Share | $34.51 | $35.92 | $139.44 | $136.36 | $133.64 |
| Shares | |||||
| Basic Shares Outstanding | 76.7M | 76.9M | 76.7M | 75.8M | 74.5M |
| Diluted Shares Outstanding | 76.7M | 76.9M | 76.7M | 75.8M | 76.2M |
| Profitability Metrics | |||||
| EBITDA | 229.8M | 219.8M | 51.2M | 390.6M | 368.4M |
| D&A | 221.4M | 214.5M | 264.8M | 287.4M | 228.7M |
| EBIT | 8.4M | 5.2M | (213.6M) | 103.2M | 139.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026